

Amendments to the Specification

Please amend the paragraph that begins on page 23, line 17 as follows:

-- The invention further encompasses methods of using and pharmaceutical compositions comprising a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, in combination with a phosphodiesterase inhibitor. Examples of phosphodiesterase inhibitors that can be used in compositions and methods of the invention include, but are not limited to, those disclosed in U.S. Patent No. 5,250,534; U.S. Patent No. 5,719,283; U.S. Patent No. 6,127,363; WO 94/28902; WO 97/03675; WO 98/06722, all of which are expressly incorporated herein by reference in their entirety. Preferred phosphodiesterase inhibitors are PDE5 and PDE6 inhibitors. Particular phosphodiesterase inhibitors include, but are not limited to, ~~sildenafil~~ sildenafil (Viagra[®]), ~~desmethylsildenafil~~ desmethylsildenafil, ~~vinopocetine~~ vinopocetine, milrinone, amrinone, pimobendan, cilostamide, enoximone, peroximone, vesnarinone, rolipran, R020-1724, zaprinast, dipyridamole, and pharmaceutically acceptable salts, solvates, hydrates, clathrates, prodrugs, optically and pharmacologically active stereoisomers, and pharmacologically active metabolites thereof.--

Please amend the paragraph that begins on page 24, line 3 as follows:

-- While all combinations of racemic and optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrate thereof, and one or more of the above-described pharmacologically active compounds can be useful and valuable, certain combinations are particularly preferred. Examples of preferred combinations include those wherein a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, is combined with one of the following:

alprazolam;	mesoridazine;	tertatolol;
brotizolam;	thioridazine;	desipramine;
chlordiazepoxide;	acetophenazine;	clonidine;
clobazam;	fluphenazine;	olanzapine;
clonazepam;	perphenazine;	methylphenidate;
clorazepate;	trifluoperazine;	buspirone;
demoxepam;	chlorprothixene;	hydroxyzine;
diazepam;	thiothixene;	tomoxetine;
estazolam;	clozapine;	sildenafil <u>sildenafil</u> ;
flumazenil;	haloperidol;	desmethylsildenafil <u>desmethylsildenafil</u> ;

flurazepam;	loxapine;	vinopocetine <u>vinpocetine</u> ;
halazepam;	molindone;	milrinone;
lorazepam;	pimozide;	amrinone;
midazolam;	risperidone;	pimobendan;
nitrazepam;	alprenolol;	cilostamide;
nordazepam;	WAY 100135;	enoximone;
oxazepam;	spiperone;	peroximone;
prazepam;	S(S)-pindolol;	vesnarinone;
quazepam;	R(R)-pindolol;	rolipran;
temazepam;	racemic pindolol;	R020-1724;
triazolam;	(S)-UH-301;	zaprinast; or
chlorpromazine;	penbutolol;	dipyridamole.--